Original Article

Split Viewer

Blood Res 2015; 50(4):

Published online December 31, 2015

https://doi.org/10.5045/br.2015.50.4.204

© The Korean Society of Hematology

Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012

Eun-Hye Park1,#, Hyewon Lee2,#, Young-Joo Won1,4, Hee Young Ju3, Chang-Mo Oh1, Cecile Ingabire1,4, Hyun-Joo Kong1, Byung-Kiu Park3, Ju Young Yoon3, Hyeon-Seok Eom2,5, Eunyoung Lee2, and Hyeon Jin Park3*

1The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Korea.

2Hematologic Oncology Clinic, National Cancer Center, Goyang, Korea.

3Center for Pediatric Oncology, National Cancer Center, Goyang, Korea.

4Department of Cancer Control and Policy, National Cancer Center, Goyang, Korea.

5Department of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.

Correspondence to : Correspondence to Hyeon Jin Park, M.D., Ph.D. Center for Pediatric Oncology, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea. Tel: +82-31-920-1654, hjpark@ncc.re.kr

Received: October 12, 2015; Revised: November 6, 2015; Accepted: December 7, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Large-scale epidemiologic analysis for hematologic malignancies will be helpful to understand the trends in incidence and survival.

Methods

The Korea Central Cancer Registry (KCCR) updated the nationwide analysis on the incidence and survival of myeloid malignancies, from the Korean National Cancer Incidence Database between 1999 and 2012. Myeloid malignancies were classified based on the International Classification of Diseases for Oncology 3rd edition (ICD-O-3).

Results

Overall 3,771 cases of myeloid diseases, which was 1.7% of all cancers, were identified in 2012. The highest incidence of myeloid malignancies was observed in age 70s and male predominance was noted (1.3:1). Acute myeloid leukemia (AML) was the most frequent subtype, followed by myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) and MDS/MPN: age-standardized incidence rates (ASR) in 2012 for each disease were 2.02, 1.95, 1.13, and 0.12 per 100,000 persons, respectively. The ASR for all myeloid malignancies was increased from 3.31 in 1999 to 5.70 in 2012 with the annual percentage change (APC) of 5.4 %. Five-year relative survival rate (RS) for myeloid malignancies has gradually improved for decades. RS changed from 26.3% to 34.8% in AML, specifically from 51.6% to 69.6% in acute promyelocytic leukemia (APL) and from 23.8% to 29.9% in non-APL AML, between 1996-2000 and 2008-2012. RS also increased from 81.8% to 87.1% in MPN, with a significant improvement in CML (from 74.5% to 85.5%), and from 27.3% to 31.7% in MDS/MPN between 2001-2005 and 2008-2012. However, there was no survival improvement in MDS during the study period (45.6% in 2001-2005 to 44.4% in 2008-2012).

Conclusion

This report updated the nationwide statistical analysis on myeloid malignancies since 2008, showing increasing incidence and improving trends in survival.

Keywords Myeloid malignancy, Incidence, Survival, Korea

Article

Original Article

Blood Res 2015; 50(4): 204-217

Published online December 31, 2015 https://doi.org/10.5045/br.2015.50.4.204

Copyright © The Korean Society of Hematology.

Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012

Eun-Hye Park1,#, Hyewon Lee2,#, Young-Joo Won1,4, Hee Young Ju3, Chang-Mo Oh1, Cecile Ingabire1,4, Hyun-Joo Kong1, Byung-Kiu Park3, Ju Young Yoon3, Hyeon-Seok Eom2,5, Eunyoung Lee2, and Hyeon Jin Park3*

1The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Korea.

2Hematologic Oncology Clinic, National Cancer Center, Goyang, Korea.

3Center for Pediatric Oncology, National Cancer Center, Goyang, Korea.

4Department of Cancer Control and Policy, National Cancer Center, Goyang, Korea.

5Department of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.

Correspondence to:Correspondence to Hyeon Jin Park, M.D., Ph.D. Center for Pediatric Oncology, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea. Tel: +82-31-920-1654, hjpark@ncc.re.kr

Received: October 12, 2015; Revised: November 6, 2015; Accepted: December 7, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Large-scale epidemiologic analysis for hematologic malignancies will be helpful to understand the trends in incidence and survival.

Methods

The Korea Central Cancer Registry (KCCR) updated the nationwide analysis on the incidence and survival of myeloid malignancies, from the Korean National Cancer Incidence Database between 1999 and 2012. Myeloid malignancies were classified based on the International Classification of Diseases for Oncology 3rd edition (ICD-O-3).

Results

Overall 3,771 cases of myeloid diseases, which was 1.7% of all cancers, were identified in 2012. The highest incidence of myeloid malignancies was observed in age 70s and male predominance was noted (1.3:1). Acute myeloid leukemia (AML) was the most frequent subtype, followed by myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) and MDS/MPN: age-standardized incidence rates (ASR) in 2012 for each disease were 2.02, 1.95, 1.13, and 0.12 per 100,000 persons, respectively. The ASR for all myeloid malignancies was increased from 3.31 in 1999 to 5.70 in 2012 with the annual percentage change (APC) of 5.4 %. Five-year relative survival rate (RS) for myeloid malignancies has gradually improved for decades. RS changed from 26.3% to 34.8% in AML, specifically from 51.6% to 69.6% in acute promyelocytic leukemia (APL) and from 23.8% to 29.9% in non-APL AML, between 1996-2000 and 2008-2012. RS also increased from 81.8% to 87.1% in MPN, with a significant improvement in CML (from 74.5% to 85.5%), and from 27.3% to 31.7% in MDS/MPN between 2001-2005 and 2008-2012. However, there was no survival improvement in MDS during the study period (45.6% in 2001-2005 to 44.4% in 2008-2012).

Conclusion

This report updated the nationwide statistical analysis on myeloid malignancies since 2008, showing increasing incidence and improving trends in survival.

Keywords: Myeloid malignancy, Incidence, Survival, Korea

Fig 1.

Figure 1.

Incident cases of myeloid malignancies in men (B) and women (C) in Korea, 2012. a)AML cases include 153 cases of APL in both genders (77 cases in men, and 76 cases in women); b)MPN cases include 458 cases of CML in both genders (288 cases in men, and 170 cases in women); c)Unknown cases include 15 cases of acute leukemia, ambiguous lineage in both genders (7 cases in men, 8 cases in women).

Abbreviations: AML, acute myeloid leukemia; MPN, myeloproliferative neoplasms; MDS, myelodysplastic syndrome; MDS/MPN, myelodysplastic/myeloproliferative neoplasms.

Blood Research 2015; 50: 204-217https://doi.org/10.5045/br.2015.50.4.204

Fig 2.

Figure 2.

Incident cases of myeloid malignancies by age group in Korea, 2012.

Abbreviations: same as in Fig. 1.

Blood Research 2015; 50: 204-217https://doi.org/10.5045/br.2015.50.4.204

Fig 3.

Figure 3.

Age-specific incidence rates of myeloid malignancies in men (A) and in women (B) in Korea, 2012.

Abbreviations: same as in Fig. 1.

Blood Research 2015; 50: 204-217https://doi.org/10.5045/br.2015.50.4.204

Fig 4.

Figure 4.

Trend in relative survival rate of myeloid malignances between 1996 and 2010 in Korea.

Abbreviations: same as in Fig. 1.

Blood Research 2015; 50: 204-217https://doi.org/10.5045/br.2015.50.4.204
Incident cases of myeloid malignancies and trend in crude incidence rates and age-standardized incidence rates in Korea from 1999 to 2012.

a)Official registration employing ICD-O-3 began in 2003 at KCCR. b)The annual percent change is statistically significantly different from zero (P<0.05)..

Abbreviations: CR, crude incidence rate; ASR, age-standardized incidence rate; APC, annual percentage change; APL, acute promyelocytic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; MPN, myeloproliferative neoplasia; MDS, myelodysplastic syndrome..


Five-year relative survival rates of myeloid malignancies by age group in Korea.

a)Official registration employing ICD-O-3 began in 2003 at KCCR..

Abbreviations: same as in Table 1..


Blood Res
Volume 59 2024

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download